UCART19

Formula :

Wikipedia: An experimental immunotherapy against leukemia using genetically modified T-cells developed by Cellectis. Unlike personalized medicine, UCART19 is hoped to be ?off-the-shelf?.[1] Developed for Chronic lymphocytic leukemia (CLL) and Acute lymphoblastic leukemia (ALL)